Vascular endothelial growth factor tyrosine kinase inhibitor AZD2171 and fractionated radiotherapy in mouse models of lung cancer

Medicine & Life Sciences

• cediranib 100%
• Protein-Tyrosine Kinases 52%
• Vascular Endothelial Growth Factor A 50%
• Lung Neoplasms 46%
• Radiotherapy 40%
• Radiation 21%
• Neoplasms 18%
• Vascular Endothelial Growth Factor Receptor 17%
• Ionizing Radiation 14%
• Heterografts 13%
• Growth 10%
• Endothelial Cells 10%
• Staining and Labeling 9%
• Vascular Endothelial Growth Factor Receptor-2 9%
• DNA Nucleotidylexotransferase 8%
• matrigel 8%
• Umbilicus 8%
• von Willebrand Factor 8%
• Group Psychotherapy 7%
• Nude Mice 6%
• In Vitro Techniques 6%
• Therapeutics 5%
• Cell Culture Techniques 5%
• Phosphorylation 5%
• Clinical Trials 4%
• Apoptosis 4%
• Blood Vessels 4%
• Lung 3%